Indian shares set to open marginally higher; Tech Mahindra in focus
BENGALURU, July 26 (Reuters) -Indian shares are likely to open marginally higher on Friday, after logging losses in the previous five sessions, with analysts expecting earnings-led stock-specific reactions to guide the intraday trajectory.
The GIFT Nifty GIFc1 was at 24,486 points, as of 8:16 a.m. IST, suggesting that the Nifty 50 index .NSEI will open slightly above its Thursday's close of 24,406.1.
Weaker-than-expected results from Reliance Industries RELI.NS, Wipro WIPR.NS, Bajaj Finance BJFN.NS, Axis Bank AXBK.NS and Nestle NEST.NS have weighed on markets through the course of the week, as did the union budget on Tuesday, in which tax hikes on capital gains in equity investments and derivatives trading were announced.
"Overall, we expect the market to continue seeing incremental moves on Friday with stock-specific action guiding the trajectory given the earnings season is in full swing," said Siddhartha Khemka, head of retail research, Motilal Oswal Financial Services.
Tech Mahindra TEML.NS will be in focus after the information technology firm beat its estimates for June-quarter revenue. The company said it expects a "better fiscal year 2025, compared with the previous one."
Asian markets were trading lower on the day, while most Wall Street equities logged losses in a choppy overnight session. MKTS/GLOB
Investors await the U.S. personal consumption expenditures (PCE) data - the Federal Reserve's preferred gauge of inflation - due after the closing bell to confirm bets of an early start of rate cuts.
Data showed on Thursday that the U.S. economy grew faster than expected in second quarter, keeping intact the expectations that the Fed will begin cutting interest rates in September.
Foreign institutional investors (FIIs) remained sellers for the third straight session on Thursday, with the outflows since union budget rising to about $1.3 billion.
STOCKS TO WATCH
** AU Small Finance Bank: Company reports a rise in net profit in June quarter, and also announces plans to apply to the Reserve Bank of India for a Universal Bank license.
** Mankind Pharma MNKI.NS: Drugmaker says it will acquire Bharat Serums and Vaccines from U.S.-based private equity firm Advent International in a deal valued at about 136.30 billion rupees ($1.63 billion).
** Cyient CYIE.NS: Company posts drop in June-quarter profit on delays in project execution.
** United Spirits UNSP.NS: Company's chief execution has been summoned by Delhi city police in liquor payments case, Reuters reported.
($1 = 83.7330 Indian rupees)
Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sherry Jacob-Phillips
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
